Erin L St. Onge, Pharm.D.
Clinical Associate Professor
Department:
Pharmacy Education and Practice
Business Phone:
(407) 313-7004
Business Email:
estonge@ufl.edu
About Erin L St. Onge
Erin St. Onge, Pharm.D., joined the faculty in July 2002 to help start the University of Florida College of Pharmacy program in Orlando.
St. Onge graduated from the University of Florida College of Pharmacy with her Doctor of Pharmacy degree with honors in 1999. Upon graduation, she completed a residency in Community Clinical Pharmacy with St. Louis College of Pharmacy/Walgreens. Dr. St. Onge accepted her first faculty position with Texas Tech University School of Pharmacy at their Lubbock campus. During her two years with Texas Tech, she gained valuable experience with their 3-campus (Amarillo, Lubbock, Dallas) distance education program. Also, she developed a community site for 3rd and 4th year students, as well as a residency program in Community Clinical Pharmacy. Dr. St. Onge and her family moved to Orlando in summer of 2002 at which time she accepted the position as Campus Director/Assistant Dean for Orlando. After 20 years in this role, St. Onge stepped down from administration to engage more with students in the classroom as a Clinical Associate Professor. Dr. St. Onge has practiced ambulatory care in a variety of settings. She currently provides clinical services via telemedicine to patients at Shell Point Retirement Community in Fort Myers. In addition to her current position with UF College of Pharmacy, she is active in national pharmacy organizations and has held numerous leadership positions in state and local pharmacy organizations. Dr. St. Onge’s interests include diabetes mellitus, cardiovascular disease, and women’s health.
Teaching Profile
Courses Taught
2017-2024
PHA5788C Patient Care 6
2020
PHA5956 Special Topics/Self-Directed Study
2018-2025
PHA5784C Pt Care 4: GI and Renal
2019
PHA5733 Year 2 Enhancement
2019
PHA5734 Year 3 Enhancement
2017-2019,2021-2025
PHA5787C Pt Care 5: Endo
2019
PHA5026C Personal and Professional Development VI
2018-2019
PHA5166L Prof Skills Lab Vi
2017-2018,2024
PHA5165L Prof Skills Lab V
2014-2018
PHA5890 Women’S Hlth Pharm
2018,2020
PHA5060 Ambulatory Care
2007,2009-2018,2018
PHA5788 Pharmacotherapy 6
2014-2015,2017
PHA5781 Patient Care I
2017
PHA5164L Prof Skills Lab Iv
2015-2016
PHA5560 Pathphys-Pt Assess I
2011-2013,2016
PHA5784 Pharmacotherapy 4
2013-2015
PHA5108L Pharmaceu Skls Lab 1
2015
PHA5101 Dosage Forms 2
2013-2014
PHA5933 Select Top Pharmacy
2011-2012,2014
PHA5239 Pharm Law and Ethics
2011-2014
PHA5782 Pharmacotherapy 2
2013
PHA5942C Intr Pha Prac Exp 2
2013
PHA5644 Adv Pharm Pract Exp 3
2010,2012-2013
PHA5783 Pharmacotherapy 3
2011
PHA5907 Research in Phar Prac
2021
PHA5787 Pharmacotherapy 5
2021-2024
PHA5922 Thinking Skills
2024
PHA5878C Pt Care 3: Cv and Pulm
Research Profile
Research Interests: Diabetes Mellitus, Cardiovascular Disease
Publications
Academic Articles
2024
Gepirone: A New Extended-Release Oral Selective Serotonin Receptor Agonist for Major Depressive Disorder
Journal of Pharmacy Technology.
[DOI] https://doi.org/10.1177/87551225241269179.
2024
Implementation of standard setting for high-stakes objective structured clinical exams
Currents in Pharmacy Teaching and Learning.
16(6):465-468
[DOI] doi.org/10.1016/j.cptl.2024.03.008.
2023
Curricular changes in times of crisis: Lessons learned
Currents in Pharmacy Teaching and Learning.
15(1):101-109
[DOI] 10.1016/j.cptl.2023.02.014.
[PMID] 36990836.
2023
Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.
39(6):291-297
[DOI] 10.1177/87551225231198700.
[PMID] 37974591.
2023
Vonoprazan: A New Potassium-Competitive Acid Blocker
Journal of Pharmacy Technology.
39(3):139-146
[DOI] 10.1177/87551225231166531.
[PMID] 37323765.
2022
Daridorexant: A New Dual Orexin Receptor Antagonist for Insomnia
Journal of Pharmacy Technology.
38(5):297-303
[DOI] 10.1177/87551225221112546.
[PMID] 36046352.
2021
Diabetes: Pharmacotherapy for Type 2 Diabetes.
FP essentials.
504:22-27
[PMID] 33970588.
2021
Minocycline Topical Foam: A New Drug for the Treatment of Acne.
The Annals of pharmacotherapy.
55(1):105-110
[DOI] 10.1177/1060028020939926.
[PMID] 32618475.
2021
Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson’s Disease.
The Annals of pharmacotherapy.
55(9):1159-1166
[DOI] 10.1177/1060028020974560.
[PMID] 33233916.
2021
Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis
Journal of Pharmacy Technology.
37(1):45-52
[DOI] 10.1177/8755122520967632.
2020
Ambulatory care elective: Introduction to core practice concepts
Currents in Pharmacy Teaching and Learning.
12(3):331-338
[DOI] 10.1016/j.cptl.2019.12.013.
2019
Exploring the Differences between Hispanic Men and Women with Type 2 Diabetes Mellitus Using the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
Food and Nutrition Sciences.
10(07):713-718
[DOI] 10.4236/fns.2019.107052.
2017
The role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Journal of Translational Internal Medicine.
5(2):79-89
[DOI] 10.1515/jtim-2017-0015.
[PMID] 28721339.
2016
Liraglutide (Saxenda) as a treatment for obesity
Food and Nutrition Sciences.
7(4):227-235
[DOI] http://dx.doi.org/10.4236/fns.2016.74024.
2015
A Review of the Treatment of Type 2 Diabetes in Children
The Journal of Pediatric Pharmacology and Therapeutics.
20(1):4-16
[DOI] 10.5863/1551-6776-20.1.4.
[PMID] 25859165.
2015
The educational use of social media sites by pharmacy students
Journal of Curriculum and Teaching.
4(1):114-121
[DOI] http://dx.doi.org/10.5430/jct.v4n1p114.
2015
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
Clinical Therapeutics.
37(6):1150-1166
[DOI] 10.1016/j.clinthera.2015.03.004.
2013
Asynchronous vs. synchronous learning in pharmacy education
Journal of Curriculum and Teaching.
2(1):63-67
[DOI] doi:10.5430/jct.v2n1p63.
2012
Approaches to management of dilemmas by leaders in academic pharmacy
Currents in Pharmacy Teaching and Learning.
4(2):78-83.e2
[DOI] 10.1016/j.cptl.2012.01.009.
2012
Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus.
P & T : a peer-reviewed journal for formulary management.
37(12):699-708
[PMID] 23319848.
2011
New options in anticoagulation for the prevention of venous thromboembolism and stroke.
P & T : a peer-reviewed journal for formulary management.
36(2):86-99
[PMID] 21559314.
2011
Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.
Expert opinion on biological therapy.
11(11):1525-32
[DOI] 10.1517/14712598.2011.610789.
[PMID] 21913874.
2011
Redesign of a Pediatric Pharmacotherapy Elective Course To Accommodate Budget Reductions
American Journal of Pharmaceutical Education.
75
2011
Treatment options for obesity and potential therapies on the horizon.
P & T : a peer-reviewed journal for formulary management.
36(5):282-301
[PMID] 21785541.
2010
Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.
Expert opinion on biological therapy.
10(5):801-6
[DOI] 10.1517/14712598.2010.481281.
[PMID] 20367248.
2010
Role of Incretin Therapies in the Management of Type 2 Diabetes Mellitus
Journal of Clinical Metabolism and Diabetes.
1(2):1-11
2010
Saxagliptin (Onglyza) for Type 2 Diabetes Mellitus
.
81:1483-1484
2010
Saxagliptin (Onglyza) for Type 2 Diabetes Mellitus
American Family Physician.
81(12):1483-1484
2009
A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.
P & T : a peer-reviewed journal for formulary management.
34(7):368-78
[PMID] 20140101.
2009
Novel Approaches to the Treatment of Type 2 Diabetes
Journal of Pharmacy Practice.
22(3):320-332
[DOI] 10.1177/0897190008326578.
2009
Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.
2:23-30
2008
Angiotensin Ii Vaccine: a Novel Approach in the Treatment of Hypertension
Expert Opinion on Biological Therapy.
8:1669-1673
[DOI] 10.1517/14712590802442419.
2008
Dpp-Iv Inhibitors: a Review of Sitagliptin, Vildagliptin, Alogliptin, and Saxagliptin
Formulary.
43
2008
Pain associated with diabetic peripheral neuropathy: a review of available treatments.
P & T : a peer-reviewed journal for formulary management.
33(3):166-76
[PMID] 19750158.
2006
Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
Annals of Pharmacotherapy.
40(7-8):1336-1343
[DOI] 10.1345/aph.1g665.
2006
Type 2 Diabetes in Children: A Growing Epidemic
The Journal of Pediatric Pharmacology and Therapeutics.
11(4):212-222
[DOI] 10.5863/1551-6776-11.4.212.
[PMID] 23115537.
2003
Antidepressant Pharmacotherapy: Considerations for the Pain Clinician
Pain Practice.
3(2):135-143
[DOI] 10.1046/j.1533-2500.2003.03020.x.
Education
Pharm.D.
1999
·
University of Florida
Contact Details
Phones:
- Business:
- (407) 313-7004
Emails:
- Business:
- estonge@ufl.edu
Addresses:
- Business Mailing:
-
6550 SANGER RD
COLLEGE OF PHARMACY
ORLANDO FL 328277445 - Business Street:
-
UF RESEARCH AND ACADEMIC CENTER AT LAKE NONA
6550 SANGER RD
ATTN: ERIN ST. ONGE
ORLANDO FL 328277445